BRG Borregaard

Borregaard ASA: EBITDA of NOK 266 million in the 3rd quarter

Borregaard ASA: EBITDA of NOK 266 million in the 3rd quarter

Borregaard’s operating revenues increased to NOK 1,260 million (NOK 1,239 million)¹ in the 3rd quarter of 2020. EBITDA² was NOK 266 million (NOK 286 million). Fine Chemicals had an improved result, whereas BioSolutions and BioMaterials had weaker results compared with the corresponding quarter in 2019. 

During the 3rd quarter, Covid-19 affected sales and results. Negative effects on demand for certain biopolymers specialities and less specialised cellulose grades are mainly related to the coronavirus situation.

For BioSolutions, higher costs related to transatlantic shipments and low demand in the US market affected the result negatively. In BioMaterials, the effect of a reduced sales volume was offset by lower wood and energy costs. For Fine Chemicals, higher sales volume and prices for bioethanol were the main reasons for the improved result. The total net currency impact on EBITDA was slightly negative compared with the same quarter in 2019.

Profit before tax was NOK 133 million (NOK 156 million). Earnings per share were NOK 1.12 (NOK 1.31).

Our third quarter results were influenced by a Covid-19 related drop in demand, particularly for some of our biopolymers specialities in the US market. We are pleased to report progress in Fine Chemicals, says President and CEO Per A. Sørlie.

Contacts:

Director Investor Relations, Jørn Syvertsen,  335

Communication Manager, Tone Horvei Bredal,

1. Figures in parentheses are for the corresponding period in the preceding year

2. Operating profit before depreciation, amortisation and other income and expenses

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

 

Attachments

EN
21/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Borregaard

ABGSC Pulp & Paper Research ... (+3)
  • ABGSC Pulp & Paper Research
  • Henrik Bartnes
  • Martin Melbye
ABGSC Pulp & Paper Research ... (+3)
  • ABGSC Pulp & Paper Research
  • Henrik Bartnes
  • Martin Melbye
 PRESS RELEASE

Borregaard ASA: EBITDA1 of NOK 440 million in the 3rd quarter

Borregaard ASA: EBITDA1 of NOK 440 million in the 3rd quarter Borregaard’s operating revenues were NOK 1,799 million (NOK 1,949 million)2 in the 3rd quarter of 2025. EBITDA1 was NOK 440 million (NOK 524 million). The result in BioSolutions increased while BioMaterials and Fine Chemicals had lower results compared with the 3rd quarter of 2024. The reduced EBITDA1 was due to lower bioethanol prices and the temporary disruption in cellulose production at the Sarpsborg site. The negative impact from this disruption amounts to approximately NOK 40 million. The improvement in the result for BioS...

 PRESS RELEASE

Borregaard ASA: Invitation to Q3 2025 announcement

Borregaard ASA: Invitation to Q3 2025 announcement 15 October 2025: Borregaard ASA (”Borregaard”, OSE ticker: BRG) Presentation of Q3 2025 results Borregaard will report third quarter 2025 results on Wednesday 22 October 2025 at 07:00 CEST. A stock exchange announcement will be made. A press release, the quarterly report and a presentation will be made available on . A presentation of the third quarter 2025 results will also be held at 08:30 CEST at ABG Sundal Collier, Ruseløkkveien 26, 8th floor, Oslo. Attendance in person is possible. The presentation can be followed live on web-TV at ...

 PRESS RELEASE

Borregaard ASA: Issuance of Commercial Paper

Borregaard ASA: Issuance of Commercial Paper Borregaard ASA has issued a commercial paper ISIN NO0013683730 of NOK 100,000,000. Start date: 14 October, 2025Maturity: 12 December, 2025Coupon: 4,20 %Organised by: DNB Markets Sarpsborg, 10 October 2025 Contact:Chief Financial Officer, Per Bjarne Lyngstad, This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.  

ResearchPool Subscriptions

Get the most out of your insights

Get in touch